nucala 100mg/ml solution for injection in pre-filled pen (autoinjector)
glaxosmithkline pharmaceutical sdn. bhd. - mepolizumab -
nucala 100mgml solution for injection in pre-filled syringe (safety syringe)
glaxosmithkline pharmaceutical sdn. bhd. - mepolizumab -
nucala 100mgml solution for injection in pre-filled pen (autoinjector)
glaxosmithkline pharmaceutical sdn. bhd. - mepolizumab -
nucala mepolizumab 100 mg powder for injection
glaxosmithkline australia pty ltd - mepolizumab, quantity: 100 mg - injection, powder for - excipient ingredients: polysorbate 80; water for injections; dibasic sodium phosphate heptahydrate; sucrose - severe eosinophilic asthma,nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see section 5.1 pharmacodynamic properties, clinical trials).,chronic rhinosinusitis with nasal polyps (crswnp),nucala is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (crswnp) with an inadequate response to intranasal corticosteroids (see section 5.1 pharmacodynamic properties, clinical 2 trials).,relapsed or refractory egpa,nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over (see section 5.1 pharmacodynamic properties, clinical trials).
nucala
glaxosmithkline nz limited - mepolizumab 100 mg/ml - solution for injection - 100 mg/ml - active: mepolizumab 100 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate disodium edetate polysorbate 80 sucrose water for injection - nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over.
nucala
glaxosmithkline nz limited - mepolizumab 100 mg/ml - solution for injection - 100 mg/ml - active: mepolizumab 100 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate disodium edetate polysorbate 80 sucrose water for injection - nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over.
nucala- mepolizumab injection, powder, for solution nucala- mepolizumab injection, solution
glaxosmithkline llc - mepolizumab (unii: 90z2uf0e52) (mepolizumab - unii:90z2uf0e52) - mepolizumab 100 mg in 1 ml - nucala is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see use in specific populations (8.4), clinical studies (14.1)] . limitations of use nucala is not indicated for the relief of acute bronchospasm or status asthmaticus. nucala is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (crswnp) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. nucala is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (egpa). nucala is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (hes) for ≥6 months without an identifiable non-hematologic secondary cause. nucala is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation [see warnings and precautions (5.1), descrip
nucala solution
glaxosmithkline inc - mepolizumab - solution - 100mg - mepolizumab 100mg - immunosuppressive agents
nucala solution
glaxosmithkline inc - mepolizumab - solution - 100mg - mepolizumab 100mg - immunosuppressive agents
nucala solution
glaxosmithkline inc - mepolizumab - solution - 40mg - mepolizumab 40mg